Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On ...
If you are wondering whether Viking Therapeutics' current share price lines up with its underlying value, you are not alone. That is exactly what this article is here to unpack. The stock recently ...
3d
Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street
Some artificial intelligence (AI)-focused companies have delivered exceptional returns over the past few years, but some ...
Investor's Business Daily on MSN
Viking Therapeutics stock gets RS rating upgrade
Viking Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating ...
Viking has a market value of about $3.5 billion, leaving it room to run if it gains product approvals and then goes on to generate revenue growth. A 10x increase would result in a market cap of $35 ...
Leerink Global Healthcare Conference 2026 March 10, 2026 10:40 AM EDTCompany ParticipantsBrian Lian - President, CEO ...
Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026. ・The subcutaneous formulation of the drug VK2735 ...
Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options begin trading this week, for the May 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to ...
Viking Therapeutics (VKTX) stock slips 1.48% despite reporting 21.9% revenue growth and 43.9% adjusted net income increase for 2025. Full analysis here.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in General Motors Co (Symbol: GM), where a total of 73,915 contracts have traded so far, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results